168 related articles for article (PubMed ID: 9726086)
1. Irinotecan: toward clinical end points in drug development.
Pazdur R
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Van Cutsem E; Blijham GH
Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
[TBL] [Abstract][Full Text] [Related]
3. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Mitry E; Ducreux M; Rougier P
Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
5. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
Cunningham D
Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008
[TBL] [Abstract][Full Text] [Related]
6. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Cunningham D; Pyrhönen S; James RD; Punt CJ; Hickish TF; Heikkila R; Johannesen TB; Starkhammar H; Topham CA; Awad L; Jacques C; Herait P
Lancet; 1998 Oct; 352(9138):1413-8. PubMed ID: 9807987
[TBL] [Abstract][Full Text] [Related]
7. Comparing irinotecan with best supportive care and infusional 5-fluorouracil: a critical evaluation of the results of two randomized phase III trials.
Wilke HJ
Semin Oncol; 1999 Feb; 26(1 Suppl 5):21-3. PubMed ID: 10213011
[TBL] [Abstract][Full Text] [Related]
8. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Schmitt C; Blijham G; Jolain B; Rougier P; Van Cutsem E
Anticancer Drugs; 1999 Jul; 10(6):617-23. PubMed ID: 10885910
[TBL] [Abstract][Full Text] [Related]
9. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Cunningham D; Glimelius B
Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Goldberg RM; Erlichman C
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093
[TBL] [Abstract][Full Text] [Related]
11. US pivotal studies of irinotecan in colorectal carcinoma.
Pitot HC
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
Lavrenkov K; Man S; Mermershtain W; Cohen Y
J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
[TBL] [Abstract][Full Text] [Related]
13. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C
Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Rothenberg ML
Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the use of irinotecan in colorectal cancer.
Cunningham D; Maroun J; Vanhoefer U; Van Cutsem E
Oncologist; 2001; 6 Suppl 4():17-23. PubMed ID: 11585970
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Van Cutsem E; Cunningham D; Ten Bokkel Huinink WW; Punt CJ; Alexopoulos CG; Dirix L; Symann M; Blijham GH; Cholet P; Fillet G; Van Groeningen C; Vannetzel JM; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
Eur J Cancer; 1999 Jan; 35(1):54-9. PubMed ID: 10211088
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan may extend survival in people with metastatic colorectal cancer.
Oncology (Williston Park); 1998 Oct; 12(10):1512. PubMed ID: 9798204
[No Abstract] [Full Text] [Related]
18. Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.
Michael M; Moore MJ
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):121-8. PubMed ID: 9726104
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
[TBL] [Abstract][Full Text] [Related]
20. Update on European adjuvant trials with irinotecan for colorectal cancer.
Douillard JY; Barbarot V; Bennouna J
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]